SCHEMBL13627989

SCHEMBL13627989

Cc1cc(C)c2c(c1)/C(=N/O)C(=O)N2Cc1cccc(Oc2ccccc2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 3/20 0.40
TDP1 Q9NUW8 1/20 0.40
CCR8 P51685 2/20 0.39
FAAH O00519 2/20 0.39
CMA1 P23946 1/20 0.38
LMNA P02545 2/20 0.38
GAA P10253 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
FFAR1 O14842 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CHRM5 P08912 1/20 0.38
MAPT P10636 3/20 0.37
TP53 P04637 2/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
IDH1 O75874 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627999 0.90 CHRM5 (0.43) ALDH1A1KDM4ETDP1CCR8FAAH
SCHEMBL13627993 0.89 CMA1 (0.51) ALDH1A1KDM4ECMA1LMNAGAA
SCHEMBL13627959 0.80 ALDH1A1 (0.50) ALDH1A1KDM4ETDP1LMNAGAA
SCHEMBL13637765 0.80 MAPT (0.37) ALDH1A1KDM4ETDP1CMA1LMNA
SCHEMBL13627985 0.79 CHRM5 (0.48) ALDH1A1KDM4ETDP1CMA1GAA
SCHEMBL13627975 0.76 TRPA1 (0.50) ALDH1A1TDP1CHRM5
SCHEMBL13627965 0.76 ALDH1A1 (0.55) ALDH1A1CCR8FAAHCHRM5TP53
SCHEMBL13627991 0.74 TP53 (0.46) MAPTTP53
SCHEMBL13628009 0.74 KMT2A (0.48) ALDH1A1LMNAMEN1KMT2AMAPT
SCHEMBL13910738 0.73 SMN1; SMN2 (0.45) ALDH1A1LMNASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
EP-1175399-B1 INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) VERTEX PHARMA (US) 2009-03-11 EP disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 ALDH1A1 4310/4885KDM4E 2171/4885TDP1 1524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.